Glioma is the most frequent primary brain tumour of the central nervous system. Its high aggressiveness and deep-seated brain lesion make it a great challenge to develop a non-invasive, precise and effective treatment approach. Here, we report a multifunctional theranostic agent that can integrate imaging and therapy into a single nano-platform for imaging-guided sonodynamic therapy (SDT). The SDT agents were fabricated by encapsulation of sinoporphyrin sodium (DVDMS) chelating with manganese ions into nanoliposomes (DVDMS-Mn-LPs). DVDMS-Mn-LPs are physiologically stable and biologically compatible, and they can produce singlet oxygen upon ultrasound irradiation to kill cancer cells. Both cell and animal studies demonstrated that SDT with DVDMS-Mn-LPs can significantly improve the antitumour growth efficiency even in the presence of skull. In addition, DVDMS-Mn-LPs are good for MR and fluorescence imaging. Thus, DVDMS-Mn-LPs reported here may provide a promising strategy for imaging-guided modality for glioma treatment.
| INTRODUCTION
Glioma is the most common primary malignant brain tumour and considered one of the most difficult curable tumours because of its typical characteristics such as rapid proliferation, strong invasiveness and unsatisfactory prognosis. [1] [2] [3] The median survival for patients is only 12-18 months. 4 In clinic practice, surgery is traditionally the initial definitive treatment option for glioma patients. Although radiotherapy, chemotherapy or their combination treatments are also widely used for consolidating the surgical effect, they indeed cause a range of side effects and seriously lower the quality of the patient's life due to their non-selective killing of malignant and normal cells. 5, 6 Therefore, it is desirable to develop alternative or complementary glioma treatment modalities for safer and more efficient killing of tumour cells that may help to extend the patient survival.
To date, massive tumour treatment strategies have emerged, including photothermal therapy (PTT), photodynamic therapy (PDT), high intensity-focused ultrasound (HIFU), radiofrequency ablation (RFA) and cryoablation. [7] [8] [9] Most of them exhibit satisfactory efficacy against various types of tumours and actually some patients are benefiting from them, such as HIFU for uterine fibroids and RFA for liver cancer. 10, 11 However, most of these modalities are not so effective for glioma treatment. An important reason may attribute to the violent histologic change from these treatments. 12, 13 These changes are usually hazardous and disabling for patients because glioma is seated in the brain, with a huge number of nerve cells around the tumour. Clinical evidence has shown that heating of brain tissue in the sonication path resulted in a secondary focus outside the target causing neurological deficit. 12 Photodynamic therapy is a mild treatment strategy, killing tumour cells through reactive oxygen species (ROS) generated from lowintensity laser irradiation on photosensitizers. 14 However, light cannot penetrate the skull, largely limiting its application in glioma treatment. Compared to PDT, sonodynamic therapy (SDT) is another approach for cancer treatment which uses ultrasound to activate sonosensitizers to generate ROS to kill cancer cells. [15] [16] [17] Different from invasive RFA and cryoablation, ultrasound is featured with noninvasiveness and high tissue penetrability, making it possible to reach and treat deep-seated tumours, especially for glioma. More importantly, ultrasound can be focused into the brain in a small volume, achieving a precise position on tumours. [18] [19] [20] [21] Although ultrasound can pass through the skull, it is of great challenge to precisely activate the sonosensizers accumulated in the glioma for efficient SDT.
Imaging-guided therapy has provided a new solution to solve this issue. [22] [23] [24] [25] [26] [27] The imaging guidance plays unique roles and shows its intrinsic advantages in cancer treatment, especially for glioma. On the one hand, it could provide useful information such as size and location of the tumour, as well as the relationship of the tumour with surrounding tissues, which can help ultrasound for determining the irradiation position and scope. On the other hand, it could also provide the optimal time window for treatment so that the ultrasound irradiation could be conducted when the sonosensitizer reaches the peaked level in the targeted lesion. On this ground, we herein report a multifunctional theranostic agent that integrates imaging and therapy functionalities into a single nano-platform for highly efficient imaging-guided SDT. Organic sinoporphyrin sodium (DVDMS) molecules were initially used as the sonosensitizer since they have been widely used in PDT and SDT for the therapy of many human tumours. [28] [29] [30] 
| Synthesis of DVDMS-Mn and preparation of DVDMS-Mn-LPs
To chelate manganese with DVDMS, manganese chloride (MnCl 2 ) was added to the DVDMS solution at a molar ratio of 2:1 (MnCl 2 :
DVDMS) for 1 hour. Excess MnCl 2 was removed using a dialysis process (MWCO = 1 kD). To prepare DVDMS-Mn-LPs, DPPC, Cholesterol and DSPE-PEG 2000 were dissolved in chloroform in a 55:40:5 molar ratios. The chloroform was removed under a nitrogen flow until uniform phospholipid films were formed. The phospholipid films were further dried for over 3 hour under vacuum, followed by hydration at 65°C with double-distilled water containing DVDMSMn solution (DVDMS = 1 mg/mL) to obtain a final total lipid concentration of 20 mg/mL. After hydration, the mixed solutions were sonicated in a bath ultrasonic oscillator until it became pellucid.
To remove the unbound fraction of DVDMS-Mn, the liposomes were ultracentrifuged at 100 000 g for 30 minutes at 4°C.
| Characterization of DVDMS-Mn-LPs
The resulting DVDMS-Mn-LPs were subjected to TEM scanning 
| Detection of ROS in DVDMS-Mn-LPs
2′,7′-dichlorofluorescin diacetate, which was highly sensitive to ROS, 
| Cellular uptake
The U87 human glioma cells were cultured in high glucose DMEM 
| Biocompatibility assay
U87 cells were cultured in standard cell media. Cells were first seeded into 96 well plates and then incubated with free DVDMS or DVDMS-Mn-LPs with different concentrations for 24 hour. The standard CCK8 assay was used to determine relative cell viabilities.
| In vitro cell SDT
Six groups were involved in this study, including the untreated control 
| In vitro cellular ROS detection
As for single oxygen detection, the probe reagent (DCFH-DA) was dis- 
| In vivo imaging

| Histological analysis
After therapy, the mice were sacrificed by standard decapitation, and the tumours and major organs (heart, liver, spleen, lung and kidney) were harvested, fixed with 10% formalin and embedded in paraffin. 7-μm sections were cut with a paraffin slicing machine, followed by staining with hematoxylin-eosin (H&E) dyes. Tumour apoptosis was assessed by TUNEL assay according to the product instruction. Tumor proliferation potential was also assessed by immunohistochemistry staining through detecting the expression level of PCNA and Ki67, which were representative markers of tumour cell proliferation. The images were acquired on a biological inverted microscope (Olympus IX71).
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| Statistical analysis
Statistical analysis was carried out with SPSS version 19.0. All of the data represent mean values ± standard deviation of independent measurements. Statistical analysis was performed with a one way ANOVA. Differences were considered significant at *P < 0.05 and very significant at **P < 0.01.
| RESULTS
| Synthesis and characterization of DVDMS-
Mn-LPs
As shown in Figure 1A presented the synthesis process of DVDMS- 
| Cellular uptake and in vitro SDT
The cell uptake behaviour of DVDMS-Mn-LPs was investigated on U87 cancer cells through fluorescence microscopy and flow cytometry. As shown in Figure 5A PDT plus skull produced much less ROS than that of SDT plus skull.
| Dual-modal imaging in vivo
The cross-section T 1 -weighted MR images were acquired at different 
| Imaging-guided in vivo SDT
The SDT effect in vivo was shown in Figure 7E . 27, [34] [35] [36] [37] In our study, the r 1 value for DVDMS-MnLPs was about 4-fold higher than that of the clinical approved Magnevist due to increased local concentration of Mn 2+ and lowered molecular tumbling rate in those nanocarrier systems. [34] [35] [36] [37] Given that the generation of ROS plays an important role in SDT of tumour treatment, the potential of DVDMS-Mn-LPs to generate ROS was determined using 2′, 7′-dichlorofluorescin diacetate as a typical probe. 23, 8 The probe will be deacetylated by cellular esterases to non-fluorescent 2′,7′-Dichlorodihydrofluorescin (DCFH), which is rapidly oxidized to highly fluorescent 2′,7′-Dichlorodihydrofluorescein (DCF) by ROS. These results clearly revealed that the DVDMS-Mn-LPs could act as an effective SDT sonosensitizer for the generation of toxic ROS (Figure 4 ).
The low cytotoxicity is especially important for a SDT agent to guarantee its biological safety when it is intravenously injected into animal or human body before receiving ultrasound irradiation. Additionally, the previous reports have shown that free DVDMS had obvious cytotoxicity to some cells, even if at lower concentrations (0.5 μg/mL). 24, 29 Our study provides a safer DVDMS formulation which has no obvious cell damage below 20 μg/mL DVDMS concentration before they receive laser or ultrasound irradiation ( Figure 5 ).
Although a large amount of literatures available suggested that PDT has promising applications in superficial tumours, our results imply that PDT is much less effective in the treatment of tumours seated in deep tissues while SDT is featured with high efficiency for solving this critical issue, especially in the treatment of brain tumours. 
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Because low frequency ultrasound has a strong penetrability through the mouse skull and focus into the brain in a small volume, achieving a precise position on tumours. [18] [19] [20] [21] DVDMS-Mn-LPs not only could be used as dual-modal contrast agents for MRI and fluorescence imaging in vitro but also in vivo.
Free DVDMS could be quickly excreted with a low tumor accumulation amount, but DVDMS-Mn-LPs accumulated in tumour effectively ( Figure 7) . The reasons may be attributable to the passive tumour targeting by enhanced permeability and retention effect. In fact, the previous reports had demonstrated that nanoparticles could permeate into brain tumours due to the destruction of blood brain barrier. 39, 40 All these results showed that the DVDMS-Mn-LPs successfully integrated two imaging modalities into a single nanoscale system, which provided the basis for further imaging-guided treatment experiments.
With the assistance of imaging guidance, the ultrasound beam could be precisely and flexibly positioned to the whole tumour. Both the SDT treatment and SDT plus skull treatment could inhibit the growth of tumours, supported that SDT but not PDT has greater antitumour efficacy for glioma treatment. The SDT and SDT plus skull groups had no significant difference of the therapeutic efficacies, suggesting that the low frequency ultrasound has a strong penetrability through the mouse skull. All these results indicate that the SDT with DVDMS-Mn-LPs is a safe and effective glioma treatment technique. 
| CONCLUSIONS
